Drug Trial Radar · NCT03328078
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Dec 28, 2017
Primary completion
Jul 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Curis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.
Conditions
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
- Relapsed Primary Central Nervous System Lymphoma
- Refractory Primary Central Nervous System Lymphoma
Interventions
EmavusertibDrug
Emavusertib will be provided as a tablet dosage form to be taken BID.
IbrutinibDrug
Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)Time frame: 12 months
- Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs)Time frame: 12 months
- Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability dataTime frame: 12 months
- Part B: Overall Response Rate (ORR) in participants with R/R PCNSLTime frame: 18 months
- Part C: ORR in participants with R/R PCNSLTime frame: 18 months
Locations
45 sites in 7 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Mayo Clinic
Phoenix, Arizona · Completed
City of Hope
Duarte, California · Recruiting
Providence St. John's Health Center
Santa Monica, California · Recruiting
UCLA Department of Medicine - Hematology/Oncology
Santa Monica, California · Withdrawn
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut · Completed
Mayo Clinic
Jacksonville, Florida · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Fred and Pamela Buffett Cancer Center
Omaha, Nebraska · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Completed
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Mt Sinai
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Withdrawn
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center, Duke Cancer Center
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Providence Neurological Specialties West
Portland, Oregon · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Completed
UPMC Hilman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Completed
UT Southwestern Medical Center
Dallas, Texas · Active not recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Swedish Cancer Institute
Seattle, Washington · Completed
University of Washington Medical Center
Seattle, Washington · Recruiting
Všeobecná fakultní nemocnice v Praze
Prague, Czechia · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Hopital de la Timone
Marseille, France · Recruiting
Hospital Pitie Salpetriere
Paris, France · Recruiting
Institut Curie Hospital
Paris, France · Recruiting
Hematology Department Soroka UMC / Heanatology Department
Beersheba, Israel · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Hadassah Medical Center / Ein-Carem
Jerusalem, Israel · Recruiting
Università di Torino Croce e Carle
Cuneo, Italy · Recruiting
SODc Ematologia Azienda Ospedaliera Universitaria Careggi
Florence, Italy · Recruiting
IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy · Recruiting
IRCCS San Raffaele Scientific Institute
Milan, Italy · Recruiting
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, Poland · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.